ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Telix Pharmaceuticals Limited reports that an oral presentation of the recently finished pivotal Phase III ZIRCON study of TLX250-CDx (Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) will take place at the upcoming 2023 ASCO GU Symposium, which will take…